Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Central Nervous System Depressants

All Drugs and Chemicals

Hematinics

Anti-Infective Agents

Anesthetics

Liver Extracts

Ethanol

The Combined Treatment: patients undergo a surgical operation of ipsilateral liver lobe devascularization and four weeks later after the operation percutaneous alcohol injection sessions.

This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (\> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.

Combined Treatment

Osama M Elsanousi, MD

Assessment of the long-term outcome of combined ipsilateral liver lobe devascularization (ILAD) and alcohol injection of the large hepatocellular carcinoma (HCC): single center non-randomized trial.

Assessment of the overall (OS); one year; two years and three years' survival rates; the disease free survival (DFS) and the tumor response rate in the patients undergoing Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment (CILDAT) of the Large HCC. This is a prospective non randomized trial carried out at the Ribat University Hospital between May 2017 to April 2020.

Prospective, non-randomized and time series clinical trial.

Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma

Long Term Outcome of Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment (CILDAT) of the Large Hepatocellular Carcinoma (HCC)

The percentage of patients who are still alive for three years after they started CILDAT for their large HCC.

Percentage of HCC patients who are alive and well (without a recurrence of their HCC) 3 years after CILDAT

Incidence of post CILDAT Clavien-Dindo comlicatins grade 3b or more.

Incidence of post CILDAT Common Terminology Criteria for Adverse Events (CTCAE v4.03) grade

Mean percentage reduction in the sizes of the patients' tumors

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma	NCT03138044	Hepatocellular ...	Combined Treatm...	15 Years - 75 Years	The National Ribat University
Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma	NCT03138044	Hepatocellular ...	Combined Treatm...	15 Years - 75 Years	The National Ribat University

Spots Global Cancer Trial Database for ipsilateral liver lobe devascularization